Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
RYE, N.Y., Aug. 26, 2013 /PRNewswire/ — Curemark, a drug research and development company focused on neurological disorders, announced today that it has entered into a collaborative research agreement with the VTT/MSI Molecular Sciences Institute (MSI) in Berkeley, CA.
Founded in 1996 by Nobel-prize winner Sydney Brenner, MSI is an independent, not-for-profit research institute. In 2011, MSI created a partnership in bioengineering with VTT (Technical Research Centre of Finland) that is now known as the VTT/MSI Molecular Sciences Institute. VTT/MSI’s Center for Bioengineering strives to contribute to the understanding of biology to improve human health and positively impact society.
Curemark’s Chief Scientific Officer Dr. Matthew Heil said, “Tapping into MSI’s expertise will deepen our knowledge of the full nature of our proprietary enzyme’s biological properties. We expect this research will lead to multiple additional indications and formulation possibilities, which will benefit people with unmet medical needs.”
Dr. Orna Resnekov, VTT/MSI Director, echoed Dr. Heil’s sentiments. “We are excited to work with Curemark, the leader in novel therapies for autism, to advance the company’s exciting research and development program,” she said.
Curemark is currently developing a treatment for autism, CM-AT, which the U.S. Food and Drug Administration (FDA) has granted its Fast Track designation. The FDA Fast Track program facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to meet unmet medical needs.
Curemark previously announced successful preliminary discussions with the FDA regarding the anticipated future filing of the company’s New Drug Application (NDA) for CM-AT.
About Curemark LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about the company’s innovative science, visit www.curemark.com.
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark LLC